CORDRAN (flurandrenolide) by Molecular Devices is clinical pharmacology cordran is primarily effective because of its anti-inflammatory, antipruritic, and vasoconstrictive actions. Approved for corticosteroid [epc]. First approved in 1963.
Drug data last refreshed 2h ago · AI intelligence enriched 6d ago
CORDRAN (flurandrenolide) is a topical corticosteroid lotion approved in 1963 for inflammatory and pruritic skin conditions. It works by stabilizing cellular and lysosomal membranes to reduce inflammation, suppress immune response, and provide vasoconstrictive effects. The drug is absorbed through the skin and metabolized hepatically before renal excretion.
This established product with low current spending (~$3M annually) is approaching loss of exclusivity, signaling a mature commercial team focused on defending share against generics rather than growth.
CLINICAL PHARMACOLOGY Cordran is primarily effective because of its anti-inflammatory, antipruritic, and vasoconstrictive actions. The mechanism of the anti-inflammatory effect of topical corticosteroids is not completely understood. Corticosteroids with anti-inflammatory activity may stabilize…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Worked on CORDRAN at Molecular Devices? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
CORDRAN offers limited career growth due to its mature LOE-approaching status and minimal linked job openings (0 identified). Roles on this product focus on defending market share, managing generic transition, and optimizing pricing rather than innovation or expansion.